Clinical trials: T-Cell Lymphocytic Leukemia
B Acute Lymphoblastic Leukemia/Lymphoma
BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
This study is a single-arm, multicenter clinical trial of dose escalation and dose expansion.
- Trial name
- NCT07196111
- Testing
- BAFFR CAR-T
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality.
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia
- Trial name
- HAPLOTAB (NCT05236764)
- Testing
- CliniMACS
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Baylor College of Medicine
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with relapsed lymphoma. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT01258998
- Testing
- Akt inhibitor MK2206, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)
RATIONALE: BI 2536 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of BI 2536 in treating patients with refractory…
- Trial name
- NCT00243087
- Testing
- BI 2536
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
Non-Hodgkin's Lymphoma, Multiple
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells.
- Conditions
- Non-Hodgkin's Lymphoma, Multiple, Mycosis Fungoides, Hodgkin's Lymphoma
- Trial name
- NCT01609816
- Testing
- Dasatinib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Chronic Myeloproliferative Disorders, Leukemia
Pyroxamide in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of pyroxamide in treating patients who have advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00042900
- Testing
- pyroxamide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
B Cell Lymphoma, B-cell Acute Lymphoblastic Leukemia
CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
The primary objective of this study is to evaluate the safety and clinical activity of anti-CD19 Chimeric Antigen Receptor T cells (KD-019 CAR-T)infusion in the treatment of relapsed/refractory B-cell Lymphoma and B-cell acute…
- Trial name
- NCT03854994
- Testing
- Anti-CD19 CAR-T Cells Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Yan'an Affiliated Hospital of Kunming Medical University
Adult Acute Lymphocytic Leukemia T-cell, Lymphoma, Lymphoblastic
Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath
This study tests the effectivity and tolerability of treatment with alemtuzumab (MabCampath) in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or T-lymphoblastic lymphoma.
- Trial name
- NCT00199030
- Testing
- Alemtuzumab (MabCampath), Cladribine
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Goethe University
Lymphoma, Small Intestine Cancer
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00049712
- Testing
- etaracizumab
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Hematologic Malignancy, Acute Leukemia
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07710781
- Testing
- Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated
- Volunteers
- 300 people
- Sponsor
- Ossium Health, Inc.
Leukemia, Lymphoma
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
RATIONALE: Giving chemotherapy drugs, such as fludarabine and melphalan, before a donor bone marrow transplant or peripheral blood stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00008307
- Testing
- anti-thymocyte globulin, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Leukemia
Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- LAL0904 (NCT00458848)
- Testing
- asparaginase, daunorubicin hydrochloride, etoposide
- Where
- 66 sites in Italy
- Volunteers
- 470 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia Lymphocytic Acute (ALL) in Relapse, Leukemia Lymphocytic Acute (All) Refractory
CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.
This is a first-in-human trial proposed to test CD19-specific CAR-T cells with edited endogenous HPK1 (XYF19 CAR-T cells) in patients with relapsed or refractory CD19+ leukemia or lymphoma.
- Conditions
- Leukemia Lymphocytic Acute (ALL) in Relapse, Leukemia Lymphocytic Acute (All) Refractory, Lymphoma, B-Cell, CD19 Positive
- Trial name
- NCT04037566
- Testing
- XYF19 CAR-T cell, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xijing Hospital
Leukemia, Lymphoma
506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Clinical trial to study the effectiveness of 506U78 in treating patients who have relapsed or…
- Trial name
- NCT00003837
- Testing
- nelarabine
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
RATIONALE: Bone marrow from donors may be able to treat patients with severe aplastic anemia and patients whose bodies have rejected previous bone marrow transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00005852
- Testing
- anti-thymocyte globulin, filgrastim, muromonab-CD3
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
This phase II trial studies how well combination chemotherapy and dasatinib works in treating participants with Philadelphia-positive or B-cell receptor-ABL positive acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive
- Trial name
- NCT00390793
- Testing
- Cyclophosphamide, Cytarabine, Dasatinib
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003406
- Testing
- carboplatin, docetaxel, ifosfamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cancer Treatment Centers of America
B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 in paediatric or young adult patients with relapsed or refractory B cell acute lymphoblastic leukaemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia
- Trial name
- AMELIA (NCT03289455)
- Testing
- AUTO3 (CD19/22 CAR T cells
- Where
- 3 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Autolus Limited
Lymphoma
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00290706
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
Non-Hodgkin's Lymphoma (disorder), Acute Lymphoid Leukemia, Disease (disorder)
First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies
This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).
- Trial name
- NCT05348889
- Testing
- 1A46 Injection
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Chimagen Biosciences, Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.